Conditions

Long-term mortality of patients with ischemic heart disease is independently predicted by diabetes…. Anna Norhammar, MD, PhD, of the cardiology unit in the department of medicine at Karolinska Institutet in Sweden, said during her presentation, “Diabetes is common among patients with heart failure that report ischemic heart disease and it’s …

“An interaction of genetic risk with physical activity on incident type 2 diabetes that appears to be driven principally through genetic risk to insulin resistance.”…  Yann C. Klimentidis, PhD, of the University of Arizona Mel and Enid Zuckerman College of Public Health in Tucson, and colleagues wrote, “It has been …

Besides sulfonylureas, GLP-1RA can also be a treatment option for HNF1A diabetic patients…. Maturity-onset diabetes of the young adults (MODY) is responsible for 1-2% of all cases of diabetes. HNF1A diabetes is caused by loss of B-cell functions. It is usually misclassified as type 1 diabetes due to common hyperglycemic …

No effect of tight glycemic control on mortality or major cardiovascular events in long-term follow-up of the ADVANCE trial….  The Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE study) assessed the effects of routine blood-pressure lowering and strict glucose control in a broad cross …

Promising trial showed safe restoration of near-normoglycemia in type 1 diabetes…. Islet transplantation is a well-established therapeutic treatment for a subset of patients with difficult to control type 1 diabetes mellitus. Before the Edmonton Protocol, only 9% of the 267 islet transplant recipients since 1999 were insulin independent for more …

Changing the type of desks students use in schools could impact the health of our nation…. Obesity is a big concern and some adults are opting to use standing desks in favor of their standard office chairs as a way to avoid sitting during long hours at work, believing that …

Dr. Stanley Schwartz introduces himself briefly and talks about how much he enjoying his “working retirement” and actually get more academic work done since he left academia. He also says that he is “having great fun taking care of my patients and advacning the ideas I come up with as …

Dr. Stanley Schwartz talks about his groundbreaking presentation at the 2014 ADA in which he outlined a new approach to classifying diabetes based on the health of the patient’s beta-cells. He explains in detail here how the current system of classification is full of contradictions and overlap between different types …

Dr. Stanley Schwartz talks about choosing the right drugs for each individual patient, and which ones should be first tier choices, which ones second, and the efficacy we should be looking for from them….   More videos in this series with Dr. Schwartz Stanley Schwartz, MD, FACP, FACE: Introduction, ADA …

Dr. Stanley Schwartz relates his overwhelmingly positive experience treating patients with newer drug therapies such as GLP-1 agonists and SGLT-2 inhibitors. He explains that he will sometimes put patients, on the very first day of their visit, on these medications when their A1c’s are very high and, one month later, …